The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
100
3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
placebo
Yale Center for Clinical Investigation, Yale University
New Haven, Connecticut, United States
Latency to Initiate Ad-lib Smoking Session
latency to initiate smoking (in minutes) during a 50-minute period.
Time frame: 50 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.